ofa semaglutide GLP-1 Weight Loss Medications Young people's use of diabetes

From a therapeutic benefit standpoint, impaired GLP-1 secretion mediated by blood glucose has been observed in MASLD patients

It has been used off-label for weight loss, with growing interest in its formal approval for obesity treatment

This is especially important when more than one person is caring for the patient, to prevent accidental repeat dosing

By introducing the GIP (glucose-dependent insulinotropic polypeptide) component found in tirzepatide, many people find they can break through those stubborn stalls and continue their progress toward their health goals

doi: 10.1186/s12866-024-03683-w 66 SilvennoinenJRisteliLKarttunenTRisteliJ

evidence-based intensive behavioral therapy